文化傳信(00343.HK)夥科大訊飛(002230.SZ)及仿腦訂AI戰略框架協議
文化傳信(00343.HK)公佈,於本月18日,其間接全資附屬飛龍芯類腦智能科技、科大訊飛(002230.SZ)及仿腦訂立戰略框架協議,自框架協議日期起爲期三年。
框架協議訂約方同意就人工智能技術進行交流與合作。訂約方擬推進和探索中文AI的聯合研究及開發;共同開發飛龍芯,一款離線中文語音識別芯片;打造中文AI語音識別和理解芯片標杆;及增加智能芯片產品的市場份額。訂約方將就合作項下的任何具體和特定項目訂立正式協議。
訂約方預計,飛龍芯原型將會在今年底問世,並計劃於2023年第一季度推出飛龍芯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.